GUIDED THERAPEUTICS INC
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
GTHPStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit Number | Exhibit Description |
| 3.1 | Restated Certificate of Incorporation, as amended through November 3, 2016 (incorporated by reference to Exhibit 3.1 to the annual report on Form 10-K filed March 15, 2016) |
| 3.2 | Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed March 23, 2012) |
| 3.3 | Amended and Restated Certificate of Incorporation, (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed November 15, 2018) |
| 3.4 | Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 3.5 | Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.5 to the annual report on Form 10-K filed April 5, 2021) |
| 3.6 | Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock (incorporated by reference to Exhibit 3.6 to the annual report on Form 10-K filed April 5, 2021) |
| 3.7 | Certificate of Designation of Preferences, Rights and Limitations of Series F-2 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on June 10, 2021) |
| 3.8 | Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock (incorporated by reference to Exhibit 3.8 to the annual report on Form 10-K filed March 30, 2022) |
| 3.9 | Certificate of Amendment to the Certificate of Incorporation of Guided Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on January 7, 2022) |
| 10.1* | Form of Promissory Note dated April 1, 2025 issued to 1800 Diagonal Lending LLC |
| 10.2* | Form of Securities Purchase Agreement dated April 1, 2025 with 1800 Diagonal Lending LLC |
| 10.3* | Form of Promissory Note dated May 1, 2025 issued to 1800 Diagonal Lending LLC |
| 10.4* | Form of Securities Purchase Agreement dated May 1, 2025 with 1800 Diagonal Lending LLC |
| 10.5* | Form of $75,000 Promissory Note dated May 2, 2025 issued to John Gould |
| 10.6* | Form of Warrants dated May 2, 2025 issued to John Gould |
| 10.7* | Letter from the Compensation Committee of the Board of Directors of Guided Thereaputics, Inc. to Mark Faupel, dated June 3, 2025, approving revised compensation package |
| 31* | Rule 13a-14(a)/15d-14(a) Certification |
| 32* | Section 1350 Certification |
| 101.1* | Interactive data files for Guided Therapeutics, Inc. 's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, formatted in Inline XBRL: (i) the Unaudited Condensed Consolidated Balance Sheets; (ii) the Unaudited Condensed Consolidated Statements of Income; (iii) the Unaudited Condensed Consolidated Statements in Stockholders' Deficit; (iv) the Unaudited Condensed Consolidated Statements of Cash Flows; and (v) the Notes to the Unaudited Condensed Consolidated Financial Statements. |
| 104 | The cover page from Guided Therapeutics, Inc.'s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (formatted in Inline XBRL and included in Exhibit 101) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.